创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

QIU Yinda, SHI Hongyi, JIANG Chengxi, LIU Zhiguo, LI Xiaokun. Research Progress on SARS-CoV-2 and Anti-COVID-19 Drugs[J]. Progress in Pharmaceutical Sciences, 2020, 44(2): 145-152.
Citation: QIU Yinda, SHI Hongyi, JIANG Chengxi, LIU Zhiguo, LI Xiaokun. Research Progress on SARS-CoV-2 and Anti-COVID-19 Drugs[J]. Progress in Pharmaceutical Sciences, 2020, 44(2): 145-152.

Research Progress on SARS-CoV-2 and Anti-COVID-19 Drugs

  • As a serious threat to public health, viral pneumonia caused by SARS-CoV-2 has a significant impact on China's economic development, social stability and international exchange. Due to the strong infectivity, fast transmission and high mortality of SARSCoV-2, and especially to the current lack of effective therapies, it is particularly urgent to develop vaccines and drugs for the treatment of COVID-19. This article reviews the sources of the virus, routes of transmission, clinical symptoms, prevention and control, and the treatment of new coronavirus pneumonia, together with the current research progress on anti-COVID-19 drugs.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return